Survanta

Survanta

beractant

Manufacturer:

AbbVie

Distributor:

Zuellig Pharma

Marketer:

Zuellig Pharma
Concise Prescribing Info
Contents
Beractant (pulmonary surfactant from natural bovine lung extr)
Indications/Uses
Prevention & treatment of resp distress syndrome (RDS) in premature infants. Prevention in premature infants <1,250 g birth wt or w/ evidence of surfactant deficiency. Rescue to treat infants w/ RDS confirmed by X-ray & requiring mechanical ventilation.
Dosage/Direction for Use
100 mg of phospholipids/kg birth wt (4 mL/kg birth wt).
Special Precautions
Rales & moist breath sounds can occur transiently after administration. Endotracheal suctioning or other remedial action is not necessary unless clear-cut signs of airway obstruction are present. Does not require reconstitution or sonication before use.
Adverse Reactions
Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.
ATC Classification
R07AA - Lung surfactants ; Used in the treatment of respiratory diseases.
Presentation/Packing
Form
Survanta intratracheal susp 25 mg/mL
Packing/Price
(vial) 4 mL x 1's; (vial) 8 mL x 1's
/thailand/image/info/survanta intratracheal susp 25 mg-ml/25 mg-ml x 4 ml?id=7b0ba239-14f1-41a0-ac11-a3cc009ee292
/thailand/image/info/survanta intratracheal susp 25 mg-ml/25 mg-ml x 8 ml?id=2797e760-fbfc-4152-8c11-a3cc009ee292
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in